Berubicin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Enzyme inhibitors |
| Catalog number | BBF-04653 |
| CAS | 677017-23-1 |
| Molecular Weight | 633.65 |
| Molecular Formula | C34H35NO11 |
| Purity | ≥95% by HPLC |
Online Inquiry
Description
Berubicin has potential antineoplastic activity. Berubicin intercalates into DNA and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis.
Specification
| Related CAS | 293736-67-1 (hydrochloride) |
| Synonyms | Daunorubicin Impurity 9; RTA 744; RTA-744; RTA744; WP 769; WP769; WP-769; 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- |
| Storage | Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years) |
| IUPAC Name | (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-phenylmethoxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione |
| Canonical SMILES | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)OCC6=CC=CC=C6 |
| InChI | InChI=1S/C34H35NO11/c1-16-33(44-15-17-7-4-3-5-8-17)20(35)11-24(45-16)46-22-13-34(42,23(37)14-36)12-19-26(22)32(41)28-27(30(19)39)29(38)18-9-6-10-21(43-2)25(18)31(28)40/h3-10,16,20,22,24,33,36,39,41-42H,11-15,35H2,1-2H3/t16-,20-,22-,24-,33+,34-/m0/s1 |
| InChI Key | FIGNGSHKNAHTSH-JJMFXPFOSA-N |
Properties
| Appearance | Solid Powder |
| Antibiotic Activity Spectrum | Neoplastics (Tumor) |
| Boiling Point | 835.4±65.0°C (Predicted) |
| Density | 1.51±0.1 g/cm3 (Predicted) |
| Solubility | Soluble in DMSO |
Reference Reading
1.Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.
Coombes RC1, Kilburn LS2, Tubiana-Mathieu N3, Olmos T4, Van Bochove A5, Perez-Lopez FR6, Palmieri C7, Stebbing J8, Bliss JM2. Eur J Cancer. 2016 Apr 25;60:146-153. doi: 10.1016/j.ejca.2016.03.001. [Epub ahead of print]
BACKGROUND: The hormonal manipulation 5-Fluoro-uracil Epirubicin Cyclophosphamide (HMFEC) trial was developed at a time of uncertainty around the dose intensity of chemotherapy given to premenopausal patients with node positive breast cancer and to the benefits of tailored endocrine therapy in such patients.
Recommended Products
| BBF-05886 | Notoginsenoside R1 | Inquiry |
| BBF-03915 | Clavulanate Potassium (1:1 mixture with silicon dioxide) | Inquiry |
| BBF-04621 | Artemisinin | Inquiry |
| BBF-05808 | Triptolide | Inquiry |
| BBF-05827 | Spliceostatin A | Inquiry |
| BBF-00586 | Brefeldin A | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
